Ocular Therapeutix, Inc.OCULNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P15
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -2.98% |
| Q3 2025 | 2.50% |
| Q2 2025 | 19.19% |
| Q1 2025 | 4.56% |
| Q4 2024 | 10.62% |
| Q3 2024 | 28.41% |
| Q2 2024 | 39.17% |
| Q1 2024 | 28.03% |
| Q4 2023 | 7.83% |
| Q3 2023 | -0.50% |
| Q2 2023 | 2.35% |
| Q1 2023 | 8.89% |
| Q4 2022 | -1.28% |
| Q3 2022 | 4.73% |
| Q2 2022 | 0.00% |
| Q1 2022 | 4.15% |
| Q4 2021 | -1.11% |
| Q3 2021 | -8.23% |
| Q2 2021 | 26.83% |
| Q1 2021 | 43.32% |
| Q4 2020 | 9.68% |
| Q3 2020 | -13.34% |
| Q2 2020 | 31.53% |
| Q1 2020 | -39.77% |
| Q4 2019 | -1.07% |
| Q3 2019 | 8.72% |
| Q2 2019 | -16.82% |
| Q1 2019 | 10.32% |
| Q4 2018 | 5.92% |
| Q3 2018 | 10.75% |
| Q2 2018 | 6.30% |
| Q1 2018 | 4.03% |
| Q4 2017 | -2.68% |
| Q3 2017 | 0.11% |
| Q2 2017 | 20.63% |
| Q1 2017 | -8.17% |
| Q4 2016 | 28.88% |
| Q3 2016 | -18.52% |
| Q2 2016 | -1.34% |
| Q1 2016 | 2.72% |